Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals

Similar documents
Multiple Factors Should Be Considered When Setting a Glycemic Goal

CASE A2 Managing Between-meal Hypoglycemia

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

The Many Faces of T2DM in Long-term Care Facilities

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010

Frailty and Type 2 Diabetes Guidelines for clinicians

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

Diabetes: Three Core Deficits

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

A Guidance Statement from the American College of Physicians

Diabetes is very common in older people, Glycaemic control in the elderly: What should we be aiming for? Article. Andrew McGovern

How to prevent iatrogenic risk with antidiabetics in older people. Prof Bourdel-Marchasson University of Bordeaux, France

Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii

Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017

Diabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

Multiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014

What s New on the Horizon: Diabetes Medication Update

The aging of the population has largely driven the epidemic

Managing diabetes in Ramadan

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Long-Term Care Updates

MOA: Long acting glucagon-like peptide 1 receptor agonist

Oral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Comprehensive Diabetes Treatment

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT

Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.

In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.

GLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration

Drug Class Review Newer Diabetes Medications and Combinations

Type. Diabetes Drugs. A Review

Oral Anti-diabetic Drugs in Older Adults with Diabetes

Finding the sweet spot: Individualized targets for older adults with Type 2 DM

Management of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE

9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends

Effective Health Care Program

Initiating Injectable Therapy in Type 2 Diabetes

Diabetes Management in New Brunswick Nursing Homes

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016

Early treatment for patients with Type 2 Diabetes

Oral and Injectable Non-insulin Antihyperglycemic Agents

What s New in Diabetes Medications. Jena Torpin, PharmD

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA

Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Treating the elderly patients with type 2 diabetes mellitus

Insulin Intensification: A Patient-Centered Approach

Current evidence on the effect of DPP-4 inhibitor drugs on mortality in type 2 diabetic (T2D) patients: A meta-analysis

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

Non-insulin treatment in Type 1 DM Sang Yong Kim

Type 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk

Diabetes Mellitus: Overview and Guidelines

Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D

Disclosures of Interest. Publications Diabetologia Key points to emphasize

Insulin Initiation and Intensification. Disclosure. Objectives

Older Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC

DIABETES DEBATE - IS NEW BETTER?

Current Clinical Practice Guideline for Diabetes Management

WHO Guidelines for Management of Diabetes in Low Resource Settings

Diabetes update - Diagnosis and Treatment

ERBP Guideline on management of diabetics with advanced CKD

American Diabetes Association 2018 Guidelines Important Notable Points

Pre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes

SGLT2 Inhibition in the Management of T2DM: Potential Impact on CVD Risk

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events

SMJ Singapore Medical Journal

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin

Diabetes Mellitus II CPG

Efficacy and Safety of Basal-Supported Prandial

Combination treatment for T2DM

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Endo 2 SLO Practice (online) Page 1 of 7

Next Steps for Clinicians

Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes

Common Drug Review Patient Group Input Submissions

How can we improve outcomes in Type 2 diabetes?

HEALTH SERVICES POLICY & PROCEDURE MANUAL

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

Update on Diabetes Canadian Society of Internal Medicine Oct 11, 2018

Hanyang University Guri Hospital Chang Beom Lee

A Clinical Context Report

Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

Pathogenesis of Type 2 Diabetes

Newer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH

Choosing a Diabetes Strategy Where to Start and Where to Go

Transcription:

Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals 1. Which one of the agents listed here is widely considered the first-line therapy in type 2 diabetes due to its well-known efficacy and safety profile, yet should be used with caution in renally impaired older adults? A. Insulin B. Sitagliptin C. Metformin D. Glyburide Metformin continues to be our workhorse; it was introduced in the mid-1990s. Renal function must be monitored periodically. [References: Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, Mcguire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668-2675. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;(4):CD002967.] 2. and can both affect cognition. A. Polypharmacy, urinary incontinence B. Engaging colleagues, meal planning C. Caregiver priorities, patient priorities D. Hyperglycemia, hypoglycemia Hypoglycemia and hyperglycemia can both affect mental status. [Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-2564.] 3. Which one of the following organizations has the most liberal goals with respect to A1c targets for older adults? A. They all have the same A1c targets for older adults B. American Geriatrics Society C. American Diabetes Association D. International Diabetes Foundation The American Geriatrics Society (AGS) has the most liberal goals, compared to the American Diabetes Association and the International Diabetes Federation. The AGS guidelines state that an older adult with poor health and significant comorbidities should have an A1c goal of between 8% and 9%. [American Geriatrics Society. Guidelines abstracted from the American Geriatrics Society Guidelines for Improving Care for Older Adults with Diabetes Mellitus: 2013 Update. JAGS. 2013;61:2020-2026. American Diabetes Association. Diabetes Care. 2014;37:S54-56; International Diabetes Federation Global Guideline, 2013.] 1

4. Assessing a patient s self-management ability, inquiring about lifestyle priorities, and consulting with family members may all be considered ways to? A. Truly engage the patient as a member of the health care team B. Win the cooperation of colleagues such as dietitians C. Become better acquainted with the older generation D. Achieve A1C targets more quickly To really engage the patient as a member of the health care team, clinicians need to have some idea of his or her self-management ability and any competing priorities. It is important to know what the patient thinks is important. [Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-2664, esp. discussion of shared decision making.] 5. According to a hazard analysis published in 2002, patients with severe hypoglycemia requiring emergency services or hospitalization are? A. at lower risk of developing any form of dementia B. at lower risk of developing Alzheimer s disease C. at higher risk of developing any form of dementia D. at higher risk of developing Alzheimer s disease only In the study by Whitmer et al, the more severe hypoglycemic events patients had, the more their hazard ratio increased, up to an almost 2-fold risk of any form of dementia (not just Alzheimer s disease). [Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565-1572.] 6. Which of the following variables must be assessed when setting glycemic targets for older adults? A. Vascular complications B. Social support systems C. Life expectancy D. Time elapsed since diagnosis E. All of the above F. None of the above A one-size-fits-all approach is not appropriate for many older individuals, and that includes people who are less motivated, potentially non-adherent, or who may have poor self-care capacities. Life expectancy and time since diagnosis are also important variables to consider when setting glycemic targets. [diagram from Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.] 2

7. Cost savings, reduced hospitalization rates, and improved monitoring for T2DM-related complications have been associated with which one of the following? A. Demonstration projects of patient-centered medical homes B. Pioneer assisted living facilities C. All pioneer accountable care organizations D. Intergenerational retirement centers Patient-centered medical homes have been studied, and demonstration projects involving patients with T2DM have been shown to impart cost savings, aid in the achievement of self-management goals, reduce hospitalization rates, and improve the monitoring of T2DM-related complications. [Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864-2883.] 8. Urinary incontinence, vision impairment, and cognitive impairment are all examples of. A. geriatric syndromes that should be considered when formulating glycemic goals for older adults B. symptoms of insulin resistance in older adults with multiple comorbidities C. sequelae of undiagnosed clinical depression in older adults with multiple comorbidities D. side effects of incretin-based therapies In addition to depression, the following geriatric syndromes should be considered: polypharmacy, cognitive impairment, urinary incontinence, injurious falls and fractures, pain, vision and hearing impairments. [Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-2664.] 9. Which one of the following would NOT be included in a list of consensus recommendations aimed at improving care for older adults with T2DM? A. Assess patients for hypoglycemia and cognitive function regularly B. Take steps to avoid physical exertion C. Choose antihyperglycemic therapies carefully D. Keep recommendations in line with patient priorities Consensus recommendations include the following: screen older adults regularly; assess patients regularly for hyperglycemia; assess the burden of treatment; keep recommendations in line with patient priorities; choose antihyperglycemic therapies carefully; individualize goals and reassess goals frequently. [Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-2664.] 3

10. Regular physical activity to stimulate muscle uptake of glucose may be considered? A. less appropriate than pharmacological approaches for older adults with a sedentary lifestyle B. less feasible if poor dietary habits are firmly established C. more feasible due to comorbidities associated with aging D. a critically important way to help older adults with T2DM to achieve their glycemic goals Non-pharmacological approaches are critically important, especially appropriate intake of carbohydrates as well as regular physical activity to stimulate muscle uptake of glucose. [Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35(12):2650-2664.] 11. With respect to the risk of hypoglycemia when added to metformin, which set of relationships between classes of agents shown below is most accurate? A. biphasic insulin > basal insulin > sulfonylureas B. GLP-1 receptor agonists > DPP-4 inhibitors > sulfonylureas C. biphasic insulin > glinides > TZDs D. sulfonylureas > biphasic insulin > GLP-1 receptor agonists Metformin is often used at baseline and carries negligible risk for hypoglycemia. Risk increases with various metformin combinations (See Figure 4). [Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012;14(9):810-820.] 12. Investigators in the ACCORD-MIND trial found a significant association between a 1% higher A1c level and? A. improved performance on cognitive function tests B. impaired performance on cognitive function tests C. increased likelihood of depressive symptoms D. decreased likelihood of depressive symptoms In a sub-study of the ACCORD trial called the ACCORD-MIND trial, investigators studied the relationship between A1c at baseline and performance on several cognitive tests.... Investigators found that a 1% higher A1c was significantly associated with worse performance on a variety of cognitive function tests. [Cukierman-Yaffe T, Gerstein HC, Williamson JD, et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care. 2009;32(2):221-226.] 4

13. Autonomic neuropathy is a risk factor for hypoglycemia in older adults. Which of the following medication classes should be avoided in an older adult with autonomic neuropathy? A. SGLT-2 inhibitors B. GLP-1 receptor agonists C. DPP-4 inhibitors D. secretagogues like the sulfonylureas Autonomic neuropathy is another risk factor for hypoglycemia in older adults. This is far more common in older adults, and when present, agents such as insulin secretagogues should be used with extreme caution. [Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009;7(6):324-342.] 14. Which one of the following is NOT normally considered a risk factor for hypoglycemia among older adults with T2DM? A. Overtreatment with antidiabetic medications B. Weight loss due to changed eating habits over time C. Dementia D. Weight gain due to sedentary lifestyle Older adults are an at-risk population for hypoglycemia for many reasons. First of all, older adults are sometimes overtreated in an effort to achieve tight glycemic control. As people age, eating habits change and they may lose weight. If A1c falls below 5.5%, the risk of hypoglycemia is greatly elevated. [Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Geriatr Pharmacother. 2009;7(6):324-342.] 15. The greatest risk of hypoglycemia derives from when combined with metformin. A. biphasic insulin B. glinides C. sulfonylureas D. basal insulin Metformin is often used at baseline and carries negligible risk for hypoglycemia. Risk increases with various metformin combinations (See Figure 4). [Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012;14(9):810-820.] 16. This agent is generally avoided in older adults with T2DM due to its 5-fold greater risk for hypoglycemia when compared to glimepiride. A. metformin B. glyburide C. sitagliptin D. empagliflozin 5

Glyburide should not be used in older adults. [Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751-755.] 17. Agents within this class of pharmaceuticals have a strong capacity to lower blood glucose levels. They are associated with significant weight loss along with the potential for nausea and vomiting during drug initiation. A. biguanides B. SGLT-2 inhibitors C. DPP-4 inhibitors D. GLP-1 receptor agonists GLP-1 receptor agonists are more powerful than DPP-4 inhibitors, so their capacity to lower blood glucose is twice as great. They can induce significant weight loss, which is a major benefit. However, some patients cannot tolerate the nausea and vomiting these agents can cause. [Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes 65 and <65 years of age: a pooled analysis from phase 3 studies. Am J Geriatr Pharmacother. 2011;9(6):423-433.] 18. These agents have a moderate capacity to lower blood glucose and depend on good renal function. Hypoglycemia risk is negligible, but risks of genitourinary tract infections and fainting are elevated. A. biguanides B. SGLT-2 inhibitors C. DPP-4 inhibitors D. GLP-1 receptor agonists SGLT-2 inhibitors cause glucose wasting through the kidneys. Hypoglycemia risk is negligible, but they carry an increased risk of genitourinary tract infections. In older adults an additional concern may be the way these agents can cause osmotic diuresis. [Mikhail N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J. 2015;108(2):91-96.] 19. Which one of the following condensed T2DM patient profiles (all age 65) would be most suited for intense pursuit of normal or near-normal A1c targets? A. Highly motivated, good adherence, high risk of hypoglycemia, diagnosed 10 years ago, established cardiovascular disease, chronic kidney disease B. Poorly motivated, diagnosed 2 years ago, chronic kidney disease, moderate risk of hypoglycemia, previous MI C. Highly motivated, recently diagnosed, chronic kidney disease, low risk of hypoglycemia, moderate microvascular complications, some hypertension D. Highly motivated, recently diagnosed, no end organ damage, low risk of hypoglycemia, early signs of microvascular 6

Treatment goals can be more intense for some patients than others. Intense treatment is most appropriate for patients who are highly motivated, have good adherence, excellent capacity for selfcare, low risk of hypoglycemia, age in their 40s, have only recently been diagnosed, and have few comorbidities. [Ismail-beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: Implications of recent clinical trials. Ann Intern Med. 2011;154(8):554-559.] 20. Which one of the following condensed T2DM patient profiles would be least suited for intense pursuit of normal or near-normal A1c targets? A. Highly motivated, recently diagnosed, no end organ damage, age 85, early signs of microvascular B. Highly motivated, recently diagnosed, no end organ damage, age 75, early signs of microvascular C. Highly motivated, recently diagnosed, no end organ damage, age 65, early signs of microvascular D. Highly motivated, recently diagnosed, no end organ damage, age 55, early signs of microvascular At the other end of the spectrum are patients with poor self-care behaviors or those who are much older, who have had diabetes for decades, and who have many comorbidities. In these patients, an A1c target somewhere above 8% is perfectly acceptable. [Ismail-beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154(8):554-559.] ### 7